Clinical Trials Logo

Filter by:
NCT ID: NCT03788031 Active, not recruiting - Amblyopia Clinical Trials

Perceptual Learning Treatment for Amblyopia

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Objectives. To develop a new treatment for amblyopia using a perceptual learning approach. Hypothesis to be tested. Our proposed experiments are designed to investigate whether practicing a grating detection task can improve vision in patients with amblyopia. Design and subjects. A total of 36 patients with amblyopia will be randomized allocated into two intervention groups: Group 1, perceptual learning therapy. Group 2, occlusion therapy. A control group comprising of 18 subjects with normal vision will be recruited for comparison. A battery of tests will be used to assess a range of visual functions before and after the treatment intervention. Study instruments. Grating acuity testing system Interventions. We have established a clinical protocol for acuity training. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to indicate the location of the stimulus. Participants will be required to undertake 20 one-hour sessions of training. Main outcome measures. Resolution acuity, visual acuity, contrast sensitivity function

NCT ID: NCT03785093 Active, not recruiting - Pregnancy Clinical Trials

Intestinal Microbiota on Allergy, Growth and Development

SMARTGenHK
Start date: November 1, 2018
Phase:
Study type: Observational

There is growing evidence that microbial programming beginning in-utero can be a central component for a balanced development of innate immunity and optimal growth and development in newborns. However, the specific types of bacteria along with their cross-talk with maternal and fetal host factors are far from being clear. The investigators hypothesize microbial compositions at different body sites of pregnant women are associated with early-life microbiota of their offspring as well as growth, neurodevelopment and the development of allergic and neurocognitive disorders. This is a prospective birth cohort study involving Chinese mother-child pairs. The investigators will follow up 120 pregnant women from first trimester until childbirth, and the child until three years of age.

NCT ID: NCT03780582 Active, not recruiting - Lung Cancer Clinical Trials

Evaluation of Use of Diagnostic AI for Lung Cancer in Practice

Start date: December 14, 2018
Phase: N/A
Study type: Interventional

This study investigates ways of improving radiologists performance of the classification of CT-scans as cancerous or non-cancerous. Participants interact with an AI to classify CT-scans under three different conditions.

NCT ID: NCT03778957 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

EMERALD-1
Start date: November 30, 2018
Phase: Phase 3
Study type: Interventional

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

NCT ID: NCT03762850 Active, not recruiting - Clinical trials for Immunoglobulin A Nephropathy

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

PROTECT
Start date: December 11, 2018
Phase: Phase 3
Study type: Interventional

To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).

NCT ID: NCT03755791 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

COSMIC-312
Start date: June 10, 2018
Phase: Phase 3
Study type: Interventional

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

NCT ID: NCT03751852 Active, not recruiting - Psychosis Clinical Trials

Body-Mind-Spirit Intervention for Women With Early Psychosis

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

This is an open-labelled randomised controlled trial (RCT) that aims to examine the effectiveness of exercise coaching approach in improving the physical activity engagement in patients with psychosis.

NCT ID: NCT03734809 Active, not recruiting - NPC Clinical Trials

NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer

Start date: May 3, 2019
Phase: Phase 2
Study type: Interventional

This is an open label, single arm, non-randomized, multi-site, phase 2 clinical trial of neoadjuvant pembrolizumab in combination with gemcitabine-cisplatin for 2 cycles,followed by concurrent pembrolizumab-cisplain-radiation, and then maintainence pembrolizumab monotherpy given every 3 weeks for a total treatment duration of 12 months, in previously untreated stage IVA ( UICC 8 th Edition ) nasopharyngeal cancer(NPC).

NCT ID: NCT03718702 Active, not recruiting - Chronic Pain Clinical Trials

The Effectiveness of an Electronic Pain Management Programme (ePain) for Working Population With Chronic Pain

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

Pain in commonly found in working population. The working population who aged from 15 to 64 is the largest portion of population in Hong Kong. Also, the prevalence of chronic pain in this population group is high. The issue requires special attention. Researches demonstrated pain affects a person in a multidimensional way. Pain induces negative effects to both the physical and psychological aspects. The levels of depression, anxiety, stress are increased and quality of life is decreased in people with chronic pain. They are interrelated to pain. As pain induced discomforts, people adopted self-initiated treatments as treatment. Pharmacological and non-pharmacological pain management interventions are commonly used. Although people used different ways to relieve the pain, they tend to bear the pain to work or take sick leave. This contributes to the work loss to the whole society. Pain service in Hong Kong is scarce in the public and private sectors. It takes months for a pain sufferer to be arranged for a pain clinic follow-up. It is possible for the pain get worsen while waiting for the pain service. The pain can be difficult to treat afterwards. As self-initiated treatments are welcomed by the pain sufferers, pain education can be focused on empowering the pain sufferers on their pain knowledge and self-management techniques. The pain self-efficacy can be enhanced. The pain sufferers can be benefited from lowering the pain intensity and negative emotions. It can be a solution to develop an online pain management programme to ease the service demand. Limited studies are found for online pain management programmes to improve the pain self-efficacy and self-management techniques. In order to fill the knowledge gap and service gap, the present study aims to evaluate an online pain management programme (ePain) in improving the self-efficacy, reduction of pain intensity, decreased levels of depression, anxiety and stress, and improving quality of life in pain management in adults with chronic pain. Participants are randomised to the intervention group or the control group.

NCT ID: NCT03706690 Active, not recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

PACIFIC-5
Start date: November 27, 2018
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable, non-small cell lung cancer (Stage III), who have not progressed following definitive, platinum-based, chemoradiation therapy.